Subscribe to RSS
Transthyretin Amyloid Cardiomyopathy in a Young Female
Discussant: Dr. Sama Rajashekhar
Presenter: An 18 years old female patient came with history of difficulty in breathing on exertion, initially New York Heart Association (NYHA) Functional Classification (FC) II for 6 months, progressed to NYHA FC III over the next 3 months. There was history of paroxysmal nocturnal dyspnea (PND) attacks and pedal edema for the last 2 months. Patient was taken to outside hospital where she was managed conservatively and symptoms improved. On presentation to our hospital she had shortness of breath (SOB) NYHA FC II.
She did not complain of chest pain, palpitations, abdominal distention, facial puffiness, reduced urine output, fever, generalized weakness, cough with or without expectoration, loss or gain in weight, skin rash, pain or swelling of joints, generalized anasarca, pain abdomen, constipation, diarrhea, melena, burning micturition, tingling numbness of limbs, and bleeding manifestations.
There were no similar complaints in the past. She takes both vegetarian and nonvegetarian diet. No history of consumption of alcohol or tobacco in any form. Having regular menstrual cycles. There was history of use of medication like diuretics, vasodilators, and β-blockers. None of the family members had any illness including cardiac disease.
Discussant: Clinical presentation of this 18 years old female, with exertional dyspnea, pedal edema, and PND attacks suggestive of decompensated heart failure (HF). The possible differential diagnoses are discussed below.
Article published online:
15 February 2022
© 2022. Women in Cardiology and Related Sciences. This is an open access article published by Thieme under the terms of the Creative Commons Attribution-NonDerivative-NonCommercial License, permitting copying and reproduction so long as the original work is given appropriate credit. Contents may not be used for commercial purposes, or adapted, remixed, transformed or built upon. (https://creativecommons.org/licenses/by-nc-nd/4.0/)
Thieme Medical and Scientific Publishers Pvt. Ltd.
A-12, 2nd Floor, Sector 2, Noida-201301 UP, India
- 1 Elliott P. Cardiomyopathy. Diagnosis and management of dilated cardiomyopathy. Heart 2000; 84 (01) 106-112
- 2 Semsarian C, Ingles J, Maron MS, Maron BJ. New perspectives on the prevalence of hypertrophic cardiomyopathy. J Am Coll Cardiol 2015; 65 (12) 1249-1254
- 3 Olivotto I, Cecchi F, Casey SA, Dolara A, Traverse JH, Maron BJ. Impact of atrial fibrillation on the clinical course of hypertrophic cardiomyopathy. Circulation 2001; 104 (21) 2517-2524
- 4 Marian AJ, Braunwald E. Hypertrophic cardiomyopathy: genetics, pathogenesis, clinical manifestations, diagnosis, and therapy. Circ Res 2017; 121 (07) 749-770
- 5 Olson LJ, Subramanian R, Ackermann DM, Orszulak TA, Edwards WD. Surgical pathology of the mitral valve: a study of 712 cases spanning 21 years. Mayo Clin Proc 1987; 62 (01) 22-34
- 6 Hanson TP, Edwards BS, Edwards JE. Pathology of surgically excised mitral valves. One hundred consecutive cases. Arch Pathol Lab Med 1985; 109 (09) 823-828
- 7 Ammash NM, Seward JB, Bailey KR, Edwards WD, Tajik AJ. Clinical profile and outcome of idiopathic restrictive cardiomyopathy. Circulation 2000; 101 (21) 2490-2496
- 8 Samuel I, Anklesaria X. Endomyocardial fibrosis in South India. Ind J Path Bact. 1960; 3: 157
- 9 Nair DV. Endomyocardial fibrosis in Kerala State. Indian Heart J 1982; 34 (06) 412-417
- 10 Maron MS, Olivotto I, Zenovich AG. et al. Hypertrophic cardiomyopathy is predominantly a disease of left ventricular outflow tract obstruction. Circulation 2006; 114 (21) 2232-2239
- 11 Seward JB, Casaclang-Verzosa G. Infiltrative cardiovascular diseases: cardiomyopathies that look alike. J Am Coll Cardiol 2010; 55 (17) 1769-1779
- 12 Vijayaraghavan G, Cherian G, Krishnaswami S, Sukumar IP. Left ventricular endomyocardial fibrosis in India. Br Heart J 1977; 39 (05) 563-568
- 13 Barros-Gomes S, Williams B, Nhola LF. et al. Prognosis of light chain amyloidosis with preserved LVEF: added value of 2D speckle-tracking echocardiography to the current prognostic staging system. JACC Cardiovasc Imaging 2017; 10 (04) 398-407
- 14 Liu D, Hu K, Störk S. et al. Predictive value of assessing diastolic strain rate on survival in cardiac amyloidosis patients with preserved ejection fraction. PLoS One 2014; 9 (12) e115910
- 15 Hu K, Liu D, Herrmann S. et al. Clinical implication of mitral annular plane systolic excursion for patients with cardiovascular disease. Eur Heart J Cardiovasc Imaging 2013; 14 (03) 205-212
- 16 Statement on sarcoidosis. Joint Statement of the American Thoracic Society (ATS), the European Respiratory Society (ERS) and the World Association of Sarcoidosis and Other Granulomatous Disorders (WASOG) adopted by the ATS Board of Directors and by the ERS Executive Committee, February 1999. Am J Respir Crit Care Med 1999; 160 (02) 736-755
- 17 Kandolin R, Lehtonen J, Airaksinen J. et al. Cardiac sarcoidosis: epidemiology, characteristics, and outcome over 25 years in a nationwide study. Circulation 2015; 131 (07) 624-632
- 18 Vita T, Okada DR, Veillet-Chowdhury M. et al. Complementary value of cardiac magnetic resonance imaging and positron emission tomography/computed tomography in the assessment of cardiac sarcoidosis. Circ Cardiovasc Imaging 2018; 11 (01) e007030
- 19 Rubin J, Maurer MS. Cardiac amyloidosis: overlooked, underappreciated, and treatable. Annu Rev Med 2020; 71: 203-219
- 20 Gupta SK, Gupta S. Sarcoidosis in India: a review of 125 biopsy-proven cases from eastern India. Sarcoidosis 1990; 7 (01) 43-49
- 21 Sharma SK, Mohan A. Sarcoidosis: an Indian perspective. In: Das AK. ed. Postgraduate Medicine. Bombay: Association of Physicians of India; 1998: 472-480
- 22 Pellikka PA, Holmes Jr DR, Edwards WD, Nishimura RA, Tajik AJ, Kyle RA. Endomyocardial biopsy in 30 patients with primary amyloidosis and suspected cardiac involvement. Arch Intern Med 1988; 148 (03) 662-666
- 23 Bokhari S, Morgenstern R, Weinberg R. et al. Standardization of 99mTechnetium pyrophosphate imaging methodology to diagnose TTR cardiac amyloidosis. J Nucl Cardiol 2018; 25 (01) 181-190
- 24 Pinney JH, Whelan CJ, Petrie A. et al. Senile systemic amyloidosis: clinical features at presentation and outcome. J Am Heart Assoc 2013; 2 (02) e000098
- 25 Grogan M, Scott CG, Kyle RA. et al. Natural history of wild-type transthyretin cardiac amyloidosis and risk stratification using a novel staging system. J Am Coll Cardiol 2016; 68 (10) 1014-1020
- 26 Gillmore JD, Damy T, Fontana M. et al. A new staging system for cardiac transthyretin amyloidosis. Eur Heart J 2018; 39 (30) 2799-2806